https://www.europeanurology.com/article/S0302-2838(15)00848-9/pdf/pi-rads-prostate-imaging-reporting-and-data-system-2015-version-2

PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2

The aim was to develop clinical guidelines for multi-parametric MRI of the prostate by a group of prostate MRI experts from the European Society of Urogenital Radiology (ESUR), based on literature evidence and consensus expert opinion. True evidence-based guidelines could not be formulated, but a compromise, reflected by “minimal” and “optimal” requirements has been made. The scope of these ESUR guidelines is to promulgate high quality MRI in acquisition and evaluation with the correct indications for prostate cancer across the whole of Europe and eventually outside Europe. The guidelines for the optimal technique and three protocols for “detection”, “staging” and “node and bone” are presented. The use of endorectal coil vs. pelvic phased array coil and 1.5 vs. 3 T is discussed. Clinical indications and a PI-RADS classification for structured reporting are presented. Key Points
 • This report provides guidelines for magnetic resonance imaging (MRI) in prostate cancer. • Clinical indications, and minimal and optimal imaging acquisition protocols are provided. • A structured reporting system (PI-RADS) is described.

https://link.springer.com/content/pdf/10.1007%2Fs00330-011-2377-y.pdf

ESUR prostate MR guidelines 2012

Flip your classroom: Reach every student in every class every day

Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.

by J. Biggs and C. Tang, Maidenhead, England,
Open University Press, 2007, 360 pp., £29.99, ISBN-13: 978-0-335-22126-4

Teaching for quality learning at university

Since quantitative apparent diffusion coefficients correlated significantly with tumor Gleason scores, diffusion-weighted MR imaging may serve as an important clinical tool by adding information about prostate cancer aggressiveness to the morphologic information provided by T2-weighted MR imaging.

/pdf/diffusion-weighted-endorectal-mr-imaging-at-3-t-for-prostate-zv2xo9g9hq.pdf

Diffusion-weighted Endorectal MR Imaging at 3 T for Prostate Cancer: Tumor Detection and Assessment of Aggressiveness

The results of our prospective study showed that a triple combination of multiparametric MR imaging, including hydrogen 1 MR spectroscopy, diffusion-weighted imaging, and contrast-enhanced MR imaging, depicts more prostate cancer areas than the use of only one or two of these modalities.

https://pubs.rsna.org/doi/pdf/10.1148/radiol.10101251

Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning.

Assessment of PI-RADS v2 for the Detection of Prostate Cancer

/pdf/areas-suspicious-for-prostate-cancer-mr-guided-biopsy-in-2pztgqrwds.pdf

Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding-multiparametric MR imaging for detection and biopsy planning

Dynamic contrast-enhanced MRI enables noninvasive analysis of prostate vascularization as well as tumour angiogenesis and capillary permeability characteristics in prostate cancers. Pharmacokinetic models summarizing the complex information provided by signal intensity-time curves for a few quantitative pharmacokinetic parameters are increasingly being used in the routine clinical setting. This review consists of two parts. The first part discusses the advantages and disadvantages of the MR pulse sequences that can be used for performing DCE-MRI and also of the most widely used pharmacokinetic parameters and models and the parameters they describe. The second part outlines the range of current and potential future clinical applications of DCE-MRI and pharmacokinetic parametric maps in patients with prostate cancer, with reference to the current scientific literature on the topic. The potential clinical applications of DCE-MRI for prostate cancer include detection, localization, and staging, differentiation of recurrent cancer and estimation of the patient’s prognosis, as well as monitoring of treatment response.

/pdf/dynamic-contrast-enhanced-magnetic-resonance-imaging-and-1q5sk3vled.pdf

Tobias Franiel

Papers

Diffusion-weighted Endorectal MR Imaging at 3 T for Prostate Cancer: Tumor Detection and Assessment of Aggressiveness

Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning.

Assessment of PI-RADS v2 for the Detection of Prostate Cancer

Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding-multiparametric MR imaging for detection and biopsy planning

Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.